ClinicalTrials.gg
CompletedNCT07323680Updated Jun 12, 2026

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects

A Phase 1 interventional study of 325 mg Oral Aspirin and 325 mg aspirin by rapid IV push in Healthy, sponsored by Rhoshan Pharmaceuticals Inc. Completed at 1 site in Czechia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Rhoshan Pharmaceuticals Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jun 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the safety, pharmacokinetics, and pharmacodynamic effects of aspirin administered intravenously with aspirin administered orally.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Rhoshan Pharmaceuticals Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each subject must meet all of the following criteria to be enrolled in this study:

    1. Healthy males and non-pregnant and no breast-feeding females, ≥ 18 and ≤ 55 years of age (on the day of ).
    2. Non-smokers or past smokers (having ceased smoking at least 6 months before the first dosing).
    3. (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 on the day of screening.
    4. The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead (ECG) results, and physical examination findings at Screening.
    5. The subject has a level with the following acceptable range at Screening: (Male: 12.8 to 17.4 g/dL (128 to 174 g/L); Female: 10.8 to 15.0 g/dL (108 to 150 g/L).
    6. The subject has liver function tests within normal limits or has results that do not show abnormalities, as judged by the investigator at Screening.
    7. The subject has estimated eGFR (CKD-EPI) ≥50 mL/min (0.833mL/sec/1.73m2) at Screening.
    8. Acceptance of use of measures during the whole study by both female and male subjects.
    9. No tattoo, body piercing or any cosmetic treatment involving skin penetration within 90 days before screening, unless evaluated by Investigator as non-significant for inclusion in the study.
    10. The subject agrees to comply with all protocol requirements.
    11. The subject can provide written informed consent.
    12. The subject must fluently speak and understand Czech.

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following criteria will be excluded from the study:

    1. The subjects has had any major illness within 3 months before dosing with study drug or any significant ongoing chronic medical illness, as judged by the investigator.
    2. The subjects has a history of active deep vein thrombosis and/or thromboembolic disorder, including history of hypothrombinemia and vitamin K deficiency.
    3. The subject has a history of neuropsychiatric disease, hypertension, cardiac failure, cerebrovascular disease, chronic respiratory disease, asthma, nasal polyps associated with asthma, hepatic or renal impairment, recent dehydration (within last 30 days), gout thyrotoxicosis or systemic lupus erythematosus and other connective tissue disorders.
    4. The subject has a history of gastrointestinal bleeding or has active gastrointestinal disease that could affect drug absorption.
    5. The subject has a history of hemorrhagic disorder.
    6. or activated partial thromboplastin time level outside the normal range at screening and check-in.
    7. The subject has an increased risk of bleeding including but not limited to: any history of a bleeding problem, any recent (within 30 days preceding the first dose of study drug) major trauma, count \<100,000 mm3
    8. The subject has a history of glucose-6-phosphate dehydrogenase deficiency.
    9. The subject has a recent history of tooth extraction within 3 weeks before dosing with study drug.
    10. The subject is a smoker or has used nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, inhalers, or "vape" devices) within 6 months before the first dose of study drug and throughout the study (including the ).
    11. The subject has a history of alcohol abuse or drug addiction within 1 year prior to check-in or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects), or use of alcohol 48 hours before dosing with study drug.
    12. The subject has a positive test result for drugs of abuse, alcohol, or cotinine at screening or before dosing with study drug.
    13. The subject has used any prescription (excluding hormonal ) or over-the-counter medications, including fish oil and other herbal or nutritional supplements and, in particular, aspirin (no aspirin-containing medications allowed at all), nonsteroidal anti-inflammatory agents (No NSAIDS allowed at all, and no acetaminophen, diclofenac, ketorolac allowed), or anticoagulation therapy within 14 days before dosing with study drug and throughout the entire study period (including the washout period).
    14. The subject has received vaccination against Varicella zoster within 6 weeks before dosing with study drug.
    15. The subject has a positive test result for COVID-19, surface antigen, virus antibody, or type 1 or 2 antibodies at screening.
    16. The subject has received the COVID-19 vaccine within 14 days before Day -3, or subjects who plan to receive a COVID-19 vaccine at any time during the study.
    17. The subject has a history of relevant drug and/or food allergies (i.e., allergy to aspirin or any , allergic skin reactions, or any significant food allergy that could preclude a standard diet in the clinical unit).
    18. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (e.g. marmalade), or alcohol-, caffeine-, poppy-, or xanthine-containing products within 48 hours.
    19. The subject is involved in strenuous activity or contact sports within 24 hours before dosing with study drug and during the study.
    20. The subject has donated blood or blood products >450 mL within 30 days before dosing with study drug.
    21. The subject has received study drug in another study within 30 days or 5 half-lives, whichever is longer, before dosing with study drug.
    22. In the opinion of the investigator, the subject is not suitable for entry into the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Rho-11 administered in Period 1, oral aspirin administered in Period 2

    Drug: 325 mg Oral Aspirin · Drug: 325 mg aspirin by rapid IV push

  • Experimental
    Oral aspirin administered in Period 1, Rho-11 administered in Period 2

    Drug: 325 mg Oral Aspirin · Drug: 325 mg aspirin by rapid IV push

Interventions

  • Drug: aspirin 325mg • Subjects will be administered 325 mg aspirin orally

  • Drug325 mg aspirin by rapid IV push

    Drug: Rho-11 Subjects will be administered 325 mg aspirin by rapid IV push

    Also known as: Rho-11

06

What researchers measure

Primary outcomes

  1. Change in serum thromboxane B2 from baseline

    Change in serum thromboxane B2 from baseline to 180 minutes post treatment

    Time frame: 1 hour before dosing and 2, 5, 10, 20, 30, 45, 60, and 180 minutes post dosing]

Secondary outcomes

  1. Urinary 11-dehydro-TXB2 levels

    Measured levels of 11-dehydro-TXB2 in urine following treatment

    Time frame: Every 12 hours from 24 hours prior to dosing to 72 hours after dosing.

  2. Urinary 2,3-dinor-6-keto-PGF1alpha

    Measured levels of 2,3-dinor-6-keto-PGF1alpha in urine following treatment

    Time frame: Every 12 hours from 24 hours prior to dosing to 72 hours after dosing.

  3. Acetylsalicylic Acid Plasma Pharmacokinetics

    Measured change in levels of acetylsalicylic acid in plasma following treatment

    Time frame: 1 hour prior to dosing, and 1,3,5,10,15,20,30, and 45 minutes and 1,1.5,2,3,6,8, and 24 hours postdosing.

  4. Salicylic Acid Plasma Pharmacokinetics

    Measured change in levels of salicylic acid in plasma following treatment

    Time frame: 1 hour prior to dosing, and 1,3,5,10,15,20,30, and 45 minutes and 1,1.5,2,3,6,8, and 24 hours postdosing.

07

Study locations

1 site
  • Quinta-Analytica s.r.o.
    Prague, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jul 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 7, 2026
StartActual
Jun 15, 2025
Primary completionActual
Jul 7, 2025
CompletionActual
Dec 12, 2025
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323680
Lead sponsor
Rhoshan Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jun 15, 2025
Primary completion
Jul 7, 2025
Completion
Dec 12, 2025
Last update
Jun 12, 2026

Study contacts

Joseph Purvis, MD
study director · jpurvis@rhoshanpharma.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion